Movement Disorder Relief

Tetrabenazine

Treatment to reduce involuntary movements in Huntington’s disease and related disorders.

Tetrabenazine is a VMAT2 inhibitor used to treat chorea associated with Huntington’s disease and other hyperkinetic movement disorders. It works by decreasing the amount of dopamine available in nerve cells, effectively reducing involuntary movements and improving patient motor control and quality of life.

Ingredients dosages:

Frequency:

Quantity:

Not sure about dosages? Don't worry, your provider will adjust or confirm your selection after checkout.

Total

$0.00

Here's what happens next:

  1. 1

    Product checkout

    We'll direct you to our product detail page where you can start the checkout process. You'll be charged for the medical consultation but the medication charge is a hold until the official provider review.

  2. 2

    Comprehensive Medical Questionnaire

    After purchase, you'll be directed to a medical assessment covering your medical history, current medications, and specific symptoms.

  3. 3

    Licensed Provider Review

    A licensed healthcare provider reviews your complete medical profile, ensuring this treatment is safe and appropriate for you.

  4. 4

    Personalized Treatment Plan

    Your provider may recommend an adjustment to your prescription based on your full medical profile before approving your treatment.

HIPAA Compliant
Certified Providers

  • Reduces chorea severity in patients with Huntington’s disease

  • Improves motor function and control in hyperkinetic movement disorders

  • May enhance daily functioning by minimizing involuntary movements

  • Effective VMAT2 inhibition shown in multiple controlled trials for Huntington’s chorea

  • Tetrabenazine: Selectively inhibits vesicular monoamine transporter 2 (VMAT2), depleting presynaptic dopamine stores and reducing excessive dopaminergic activity that causes involuntary movements

  • Start with a low dose and gradually titrate based on therapeutic response and tolerability

  • Typically administered two to three times daily with or without food

  • Monitor for symptoms of depression or suicidal thoughts during treatment

  • Avoid abrupt discontinuation to reduce withdrawal or symptom rebound